Apellis Pharmaceuticals secured FDA approval to expand the label of its complement C3 inhibitor, Empaveli (pegcetacoplan), to treat patients aged 12 and older with complement 3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). Approval followed positive phase III Valiant study results demonstrating significant reductions in proteinuria, kidney function stabilization, and clearance of complement staining. The approval represents a critical advance for patients with these rare kidney disorders with limited treatment options.